Articles Tagged With: sclerosis
-
Stem Cell Transplantation for MS Treatment
In this small study of the effect of mesenchymal stem cell treatment, both intravenous and intrathecal, in patients with progressive multiple sclerosis, the treatment was shown to be safe, and there was a trend showing some benefit in slowing disease progression, compared to the sham group. A larger randomized controlled trial is needed to confirm these early findings.
-
Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis
In this prospective, population-based study, mean lifetime heritability of amyotrophic lateral sclerosis was 52% in the entire cohort and 37% in patients devoid of any known pathogenic mutations. The highest heritability was seen in mother-daughter parings in both groups.
-
Stopping Cannabis Improves Cognitive Function in Patients With Multiple Sclerosis
The authors of a recent study evaluated the effect of discontinuing cannabis use in patients with multiple sclerosis. Stopping cannabis led to significant improvements in memory, processing speed, and executive function.
-
Systemic Immune Activation and the Course of Amyotrophic Lateral Sclerosis
Activation of the immune system has been recognized in patients with amyotrophic lateral sclerosis, and immune activation may influence the course of the disease and the speed of progression.
-
Tetracycline for Multiple Sclerosis?
One hundred forty-two patients within 180 days of their first demyelinating event were randomized to minocycline 100 mg BID vs. placebo. The unadjusted risk of conversion to multiple sclerosis within six months after randomization was 61.0% in the placebo group and 33.4% in the minocycline group. At 24 months, the effect of minocycline was not statistically significant.
-
High-dose Biotin Shows Promise for Arresting Progressive Multiple Sclerosis Disability
In this double-blind, placebo-controlled study, patients with primary or secondary progressive multiple sclerosis were randomized to receive 100 mg of pharmaceutical-grade biotin or placebo thrice daily for 12 months. The primary endpoint of an improvement in the Expanded Disability Status Scale or a decrease in timed 25-foot walk time was achieved in 12.6% of the biotin-treated patients compared to no one in the placebo group (P = 0.005).
-
Ocrelizumab for Multiple Sclerosis
A Phase III trial of ocrelizumab in primary-progressive multiple sclerosis and two Phase III trials of ocrelizumab in relapsing-remitting multiple sclerosis have demonstrated efficacy with treatment.
-
Disability in Patients with Multiple Sclerosis: A Long-Term Study
SYNOPSIS: In a long-term study, the rate of disability progression in treated relapsing and progressive, multiple sclerosis patients was lower than that reported in earlier natural history studies.